Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

From the Division of Medical Oncology (MWR, MHGF, MK, JSWB, JVT, CUB, AM-E., SK, SW, JBAGH), the BioTherapeutics Unit, Hospital Pharmacy (JH van den Berg, CN, MZ, SS), the Divisions of Pharmacy and Pharmacology (BN, JH Beijnen), Molecular Oncology and Immunology (IJ, TNS, JBAGH), Biometrics (RK, LDVW, M. van Dijk, LGG-O., LHMV, ATA, HT), Psychosocial Research and Epidemiology (RMTH, VPR, WHH), Radiology (FL), and Surgical Oncology (ACJA, WJH, MWJMW), Netherlands Cancer Institute, the Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory (MH, CV), and the Department of Medical Oncology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam (AJME), Amsterdam, the Department of Healthcare Innovation and Evaluation, Julius Center for Health Sciences and Primary Care (RMTH), the Department of Medical Oncology, University Medical Center Utrecht, Utrecht University (KPMS), Trial and Data Center, Princess Maxima Center for Pediatric Oncology (HT), and Oncode Institute itute (TNS), Utrecht, the Department of Health Technology and Services Research, University of Twente (VPR), and the Department of Medical Oncology, Medical Spectrum Twente (DP), Enschede, the Department of Medical Oncology, Erasmus Medical Center, Rotterdam (AAMV), the Department of Medical Oncology, University Medical Center Groningen, Groningen (GAPH), the Department of Medical Oncology, Amphia Hospital, Breda (MAMS-B.), the Department of Medical Oncology, Maastricht University Medical Center, Maastricht ( MJBA), the Department of Medical Oncology, Isala, Zwolle (J.-WBG), the Department of Medical Oncology, Máxima Medical Center, Eindhoven (GV), the Departments of Medical Oncology (EK), Biomedical Data Sciences (MWJMW), Hematology (TNS), and Clinical Oncology (JBAGH), Leiden University Medical Center, Leiden, the Department of Medical Oncology, Radboud University Medical Center, Nijmegen (MJB-S.), the Department of Medical Oncology, Medical Center Leeuwarden, Leeuwarden ( WEF), and th e Department of Medical Oncology, Zuyderland Medical Center, Sittard-Geleen (FWPJB) — all in the Netherlands; the Department of Oncology, National Center for Cancer Immune Therapy (THB, Ö.M., JSG, IMN, TJM, RBH, EE, M. Donia, IMS), and the Department of Plastic Surgery (LRH), Copenhagen University Hospital, Herlev, Denmark; and Melanoma Institute Australia, the Faculty of Medicine and Health, University of Sydney, and Royal Prince Alfred Hospital — all in Sydney (ACJA).

Dr. Haanen can be contacted at [email protected] or at the Division of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, the Netherlands. Dr. Svane can be contacted at [email protected] or at the National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Borgmester Ib Juuls Vej 25C, 5th fl., 2730 Herlev, Denmark.


Leave a Reply

Your email address will not be published. Required fields are marked *